Cantor Fitzgerald Starts Threshold Pharmaceuticals (THLD) at Buy

Cantor Fitzgerald initiated coverage on Threshold Pharmaceuticals (NASDAQ: THLD) with a Buy rating and a price target of $14.00.

Analyst Daniel Brims said, "We are initiating coverage of Threshold with a BUY rating and $14 target price based on TH-302’s expected peak revenues of $2B in 2025. Threshold, in collaboration with Merck KGaA, has initiated two phase 3 trials to support approval in both pancreatic cancer and soft tissue sarcoma (STS), which we expect to read out in 1Q:16 and 2H:15, respectively. We forecast commercial launch of TH-302 in 2016. We believe TH-302 is a pipeline in a single drug, and Threshold has additional trials underway in NSCLC, multiple myeloma, and an investigator-sponsored trial in GBM, which we currently do not include in our valuation but which we believe could add additional upside."

For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.

Shares of Threshold Pharmaceuticals closed at $3.96 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• TE Connectivity (TEL) PT Raised to $150 at Stifel
• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'